Results 111 to 120 of about 13,745 (204)

Budget impact and cost-utility analysis of prophylactic emicizumab versus on-demand bypassing agents for adolescent severe haemophilia A patients with inhibitors in India

Heliyon
Introduction: Severe Haemophilia A patients with inhibitors are currently being treated with bypassing agents like activated prothrombin complex concentrates (aPCC) and recombinant factor VIIa.
Yuvaraj Krishnamoorthy, Dhanajayan Govindan, Narasimhapriyan Kannan, Marie Gilbert Majella, Vishnu Shankar Hariharan, Vivek Valliappan   +5 more
doaj   +1 more source

Off-label use of recombinant factor VIIa for neonatal pulmonary hemorrhage; a single-center experience

The Turkish Journal of Pediatrics
Background. Pulmonary hemorrhage (PH) leads to acute and catastrophic deterioration in neonates, and there is no curative treatment available. Off-label use of recombinant Factor VIIa (rFVIIa) is a promising treatment to control bleeding.
Özge Serçe Pehlevan, Ayna Atayeva, Ayla Günlemez, Sibel Balcı   +3 more
doaj   +1 more source

Clinical perspectives of emerging pathogens in bleeding disorders. [PDF]

, 2006
As a result of immunological and nucleic-acid screening of plasma donations for transfusion-transmissible viruses, and the incorporation of viral reduction processes during plasma fractionation, coagulation-factor concentrates (CFC) are now judged safe ...
Bozzette, Samuel, Diamond, Michael, Koerper, Marion A, Kulkarni, Roshni, Ludlam, Christopher A, Powderly, William G, Ritchie, Bruce, Siegel, Jamie, Simmonds, Peter, Stanley, Samuel, Tapper, Michael L, von Depka, Mario   +11 more
core   +1 more source

Glanzmann’s thrombasthenia: A nightmare for hernia surgeons

Journal of Minimal Access Surgery
Glanzmann’s thrombasthenia is a rare inherited disorder affecting one in one million. It is characterised by a lack of platelet aggregation due to a defect in the platelet membrane receptor complex (αIIb/βIIIa), which mediates the aggregation of ...
Jignesh Gandhi, Aarsh Gajjar, Pravin Shinde, Yogesh Takalkar   +3 more
doaj   +1 more source

Successful Desensitization Protocol in an Infant Following Anaphylaxis Secondary to Recombinant Factor VIIa. [PDF]

Pediatr Allergy Immunol Pulmonol, 2020
Ulusoy Severcan E, Cigerci Gunaydin N, Hekimci Ozdemir H, Gulen F, Kavakli K, Tanac R, Demir E.   +6 more
europepmc   +1 more source

Recombinant human factor VIIa prevents hysterectomy in severe postpartum hemorrhage: single center study [PDF]

, 2017
Objective: To evaluate the effectiveness of human recombinant activated factor VII (rhFVIIa, NovoSeven) in avoiding hysterectomy postpartum in the management of severe postpartum hemorrhage (PPH).
Alberio, Lorenzo, Ghezzi, Fabio, Huber, Alexander W., Raio, Luigi, Surbek, Daniel V.   +4 more
core  

Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms. [PDF]

J Thromb Haemost, 2020
Keshava S, Pendurthi UR, Esmon CT, Rao LVM.   +3 more
europepmc   +1 more source

Updates in perioperative coagulation: physiology and management of thromboembolism and haemorrhage [PDF]

, 2017
Understanding of blood coagulation has evolved significantly in recent years. Both new coagulation proteins and inhibitors have been found and new interactions among previously known components of the coagulation system have been discovered.
Bombeli, T., Spahn, D. R.
core  

Use of Low-Dose Recombinant Factor Ⅶa for Uncontrolled Perioperative Bleeding. [PDF]

Dose Response, 2020
Chang ZG, Chu X, Chen W, Hu JH, Gong JW, Liu DD, He Q, Feng Z, Xiao SR, Liu YL.   +9 more
europepmc   +1 more source

Antithrombotic and hemostatic stewardship: evaluation of clinical outcomes and adverse events of recombinant factor VIIa (Novoseven^®) utilization at a large academic medical center. [PDF]

Ther Adv Cardiovasc Dis, 2020
Marsh K, Green D, Raco V, Papadopoulos J, Ahuja T.   +4 more
europepmc   +1 more source